Pharmafile Logo

Do Healthcare Providers Really Want to Go Back to In-person Meetings?

Healthcare professionals (HCPs) are increasingly seeking flexibility and convenience in their interactions with pharmaceutical and life sciences companies. This shift towards digital and blended approaches presents a valuable opportunity for life sciences organizations to enhance their communication and build stronger relationships with HCPs.

- PMLiVE

It is easy to assume that healthcare providers (HCPs) all want to go back to in-person meetings after having been confined to Zoom and Microsoft Teams meetings during the pandemic years. Anecdotally, however, we heard different things: many HCPs highlighted the convenience of the virtual format and considered this a silver lining from the long months of social and physical distancing. In a recent study by our group, the authors sought to understand this. They asked the very important question: what do HCPs really prefer when it comes to Pharma-sponsored small-group meetings such as advisory boards?

Preferred Meeting Format of HCPs

Male healthcare provider (HCP) attending a virtual meetingWhen asked about their preference for future advisory board meetings, a whopping 76% of surveyed HCPs opted for meetings with a virtual component (hybrid, real-time web, and/or asynchronous meetings). Less than a quarter of respondents preferred in-person–only meetings. Interestingly, the most popular meeting approach was found to be a mix of synchronous (real-time) and asynchronous (over-time, anytime) meetings. This finding highlights the importance of using varied formats to cater to all preferences and to avoid digital fatigue.

Another interesting finding was that the preference for hybrid meetings almost doubled between 2022 and 2023, while the preference for in-person–only meetings remained stable. In other words, while many HCPs undoubtedly do still enjoy in-person engagements, giving them the choice of how to attend will help ensure that everyone is happy…

Read the full article here.

 

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Top-5 Trends in Virtual KOL Engagement

Register now for one of our upcoming webinars (February 26-28)

Engaging with Different Perspectives – Top 10 Most Important Advisor Questions

In this quick clip, we highlight a vital tip from our 'Top 10 Most Important Advisor Questions' – essential for enhancing your virtual collaboration strategies in Pharma and Life Sciences....

Patient Advocate Engagement: A Customer Story

Learn how our client executed a series of 3 virtual touchpoints with 5 rare disease patient advocates to:- Develop a better understanding of the current treatment landscape and lived patient...

Tailored Marketing Strategies for Pharma – Top 10 Most Important Advisor Questions

In this video, we explore another crucial aspect of advisor questions when developing your virtual advisory board touchpoints – a key component for success in today's diverse healthcare landscape. 7....

Trends in Virtual Collaboration

Join us for a look at the top-5 emerging virtual collaboration trends...

Advisor Questions on Potential Data or Knowledge Gaps

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's another one to keep in...

On a journey to diverse, inclusive, and more efficient rare disease trials

Although orphan drugs represent a sizeable portion of new drug approvals, most rare diseases still lack effective treatment. Even more so than for other conditions, rare disease management contains large care...

Versatility! Top 10 benefits of virtual advisory boards

Here's another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #10. Versatility! Another major advantage of using a virtual platform...

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story

In the early lead-up to our client’s multi-center Rare Disease Phase 3 Clinical Trial, they first conducted an internal engagement planning Longitudinal Expert Engagement Plan™ (LEEP™) to conduct an informal...

New Playbook Alert: Virtual Patient Engagement

Authentic patient engagement and insight-gathering are becoming must-haves in Pharma. However, multiple obstacles remain before patient-centricity becomes more than a buzzword. In our latest playbook, we take a deep dive...